摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-硝基苯基)恶唑 | 13382-61-1

中文名称
4-(4-硝基苯基)恶唑
中文别名
4-(1,3-噁唑-4-基)硝基苯;4-(4-硝基苯基)唑;4-(4-硝基甲苯)恶唑
英文名称
4-(4-nitrophenyl)oxazole
英文别名
4-(4-nitrophenyl)-1,3-oxazole
4-(4-硝基苯基)恶唑化学式
CAS
13382-61-1
化学式
C9H6N2O3
mdl
MFCD09032979
分子量
190.158
InChiKey
STSISQMFQWBGLZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    186-188 °C(Solv: methanol (67-56-1))
  • 沸点:
    352.6±17.0 °C(Predicted)
  • 密度:
    1.333±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    71.8
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:05586b5a62d765f1f3920f8bfa7ec1e6
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-(4-Nitrophenyl)oxazole
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Nitrophenyl)oxazole
CAS number: 13382-61-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H6N2O3
Molecular weight: 190.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(4-硝基苯基)恶唑 在 palladium 10% on activated carbon 、 HATU 、 氢气N,N-二异丙基乙胺 作用下, 以 四氢呋喃甲醇 为溶剂, 20.0 ℃ 、202.66 kPa 条件下, 反应 16.0h, 生成 2,4-bis(difluoromethyl)-N-(4-(oxazol-4-yl)phenyl)pyrrolo[1,2-a]pyrimidine-8-carboxamide
    参考文献:
    名称:
    [EN] SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
    [FR] PYRROLO[1,2-A]PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
    摘要:
    该发明提供了取代的吡咯并[1,2-a]嘧啶和相关的有机化合物,包含这种化合物的组合物,医疗工具包,以及使用这种化合物和组合物治疗疾病的方法,例如高雪氏病、帕金森病、路易体病、痴呆症或多系统萎缩症等。本文描述的示例取代的吡咯并[1,2-a]嘧啶化合物包括取代的2,4-二甲基-N-苯基吡咯并[1,2-a]嘧啶-8-羧酰胺化合物及其变体。
    公开号:
    WO2016073891A1
  • 作为产物:
    描述:
    4-苯基恶唑硫酸硝酸 作用下, 反应 0.08h, 以0.847 g的产率得到4-(4-硝基苯基)恶唑
    参考文献:
    名称:
    Benzyne-oxazole cycloadducts: isolation and retro-Diels-Alder reactions
    摘要:
    DOI:
    10.1021/jo00290a025
点击查看最新优质反应信息

文献信息

  • Radical C–H Arylation of Oxazoles with Aryl Iodides: dppf as an Electron-Transfer Mediator for Cs<sub>2</sub>CO<sub>3</sub>
    作者:Zhengwei Guo、Man Li、Xue-Qing Mou、Gang He、Xiao-Song Xue、Gong Chen
    DOI:10.1021/acs.orglett.8b00530
    日期:2018.3.16
    A radical C–H arylation reaction of oxazoles with (hetero)aryl iodides using Cs2CO3 as base/electron donor and 1,1′-bis(diphenylphosphino) ferrocene (dppf) as a catalytic SET mediator is reported. The overall reaction likely follows the general base-promoted homolytic aromatic substitution mechanism through a radical-chain pathway. DFT calculations suggest that dppf forms a complex with CsCO3–, enhancing
    报道了使用Cs 2 CO 3作为碱/电子给体和1,1'-双(二苯基膦基)二茂铁(dppf)作为催化SET介体,恶唑与(杂)芳基碘化物的自由基CH芳基化反应。整个反应可能通过自由基链途径遵循一般的碱促进的均质芳族取代机理。DFT计算表明,dppf与CsCO 3 –形成络合物,增强了SET还原能力,可从ArI生成芳基。
  • [EN] SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] IMIDAZO[1,5-A]PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
    申请人:LYSOSOMAL THERAPEUTICS INC
    公开号:WO2016073889A1
    公开(公告)日:2016-05-12
    The invention provides substituted imidazo[1,5-a]pyrimidines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidine compounds described herein include substituted 2,4-dimethyl-N-phenylimidazo[1,5-a]pyrimidine-8-carboxamide compounds and variants thereof.
    这项发明提供了取代的咪唑并[1,5-a]嘧啶和相关的有机化合物,包含这种化合物的组合物,医疗工具包,以及使用这种化合物和组合物治疗患者的医疗疾病的方法,例如高雪氏病、帕金森病、路易体病、痴呆症或多系统萎缩症。本文描述的示例取代的咪唑并[1,5-a]嘧啶化合物包括取代的2,4-二甲基-N-苯基咪唑并[1,5-a]嘧啶-8-羧酰胺化合物及其变体。
  • Tetrahydro-2H-thiopyran-4-carboxamide derivative
    申请人:Kontani Toru
    公开号:US20050032855A1
    公开(公告)日:2005-02-10
    A pharmaceutical drug, particularly a novel compound useful for the prophylaxis or therapeutic treatment of various diseases involving infections with viruses of the Herpesviridae family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. N-2-[(4-Substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative where the phenyl group is substituted at position 4 with a specific five-membered or 6-membered heteroaryl group, has such great anti-virus activity that the oral dosing thereof at a low dose enabled the therapeutic treatment of the diseases.
    一种制药药物,特别是一种新型化合物,用于预防或治疗涉及Herpesviridae家族病毒感染的各种疾病,特别是各种单纯疱疹病毒感染,如水痘(水痘)通过水痘-带状疱疹病毒,水痘-带状疱疹通过潜伏水痘-带状疱疹病毒的复发感染,唇疱疹和脑炎疱疹通过HSV-1以及生殖器疱疹通过HSV-2感染。N-2-[(4-取代苯基)氨基]-2-氧乙基}四氢-2H-噻吩-4-羧酰胺衍生物,其中苯基在位置4被特定的五元或六元杂环基取代,具有如此强大的抗病毒活性,以至于以低剂量口服治疗这些疾病。
  • [EN] SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] PYRAZOLO(1,5-A)PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
    申请人:LYSOSOMAL THERAPEUTICS INC
    公开号:WO2016073895A1
    公开(公告)日:2016-05-12
    The invention provides substituted pyrazolo[l,5-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[l,5-a]pyrimidine compounds described herein include 5,7- dimethyl-N-phenylpyrazolo[l,5-a]pyrimidine-3-carboxamide compounds and variants thereof.
    这项发明提供了替代的吡唑并[1,5-a]嘧啶和相关的有机化合物,包含这些化合物的组合物,医疗工具包,以及使用这些化合物和组合物治疗医疗疾病的方法,例如高雪氏病、帕金森病、Lewy小体病、痴呆症或多系统萎缩症。本文描述的示例替代的吡唑并[1,5-a]嘧啶化合物包括5,7-二甲基-N-苯基吡唑并[1,5-a]嘧啶-3-羧酰胺化合物及其变体。
  • Converting oxazoles into imidazoles: new opportunities for diversity-oriented synthesis
    作者:Thibaut Alzieu、Johannes Lehmann、Ajay B. Naidu、Rainer E. Martin、Robert Britton
    DOI:10.1039/c3cc48467j
    日期:——
    We report the optimization of a neglected reaction for the rapid and direct conversion of oxazoles into N-substituted imidazoles. The utility of this microwave-promoted reaction for diversity-oriented synthesis is demonstrated in the preparation of >40 N-substituted imidazoles, including alpha-imidazolyl esters.
    我们报告了快速和直接将恶唑转化为N-取代的咪唑的被忽视反应的优化。微波促进反应在面向多样性的合成中的实用性在包括α-咪唑基酯在内的> 40种N-取代的咪唑的制备中得到了证明。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺